Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031076 | 1.00 | CYP3A4 (0.48) | CYP3A4ALDH1A1NPSR1KDM1ATTR | |
| SCHEMBL12107538 | 0.83 | CYP3A4 (0.54) | CYP3A4ALDH1A1NPSR1KDM1AKDM4E | |
| SCHEMBL1755262 | 0.81 | MAPT (0.49) | CYP3A4ALDH1A1NPSR1KDM1AKDM4E | |
| SCHEMBL1291043 | 0.81 | TTR (0.40) | CYP3A4TTRKDM4ERAPGEF4IDO1 | |
| SCHEMBL540384 | 0.80 | ALDH1A1 (0.40) | CYP3A4ALDH1A1TTRKDM4ECCR2 | |
| SCHEMBL29377856 | 0.80 | ALDH1A1 (0.40) | CYP3A4ALDH1A1TTRKDM4ECCR2 | |
| SCHEMBL92958 | 0.79 | S1PR1 (0.51) | CYP3A4ALDH1A1NPSR1KDM1ATTR | |
| SCHEMBL109221 | 0.79 | CYP3A4 (0.52) | CYP3A4ALDH1A1NPSR1KDM1APNMT | |
| SCHEMBL9073026 | 0.79 | CYP3A4 (0.46) | CYP3A4ALDH1A1NPSR1KDM1AKDM4E | |
| SCHEMBL3763570 | 0.79 | CYP3A4 (0.46) | CYP3A4ALDH1A1NPSR1KDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106986742-B | Synthesis method of tetrachloro-p-xylene cyclic dimer | 常州市骏佳化工有限公司 | 2020-08-04 | — | — | CN | claimed |
| EP-0714557-A1 | METHOD OF PROVIDING A FILM OF CONJUGATED, SUBSTITUTED OR UNSUBSTITUTED POLY(P-PHENYLENE VINYLENE) ON A SUBSTRATE BY CHEMICAL VAPOUR DEPOSITION (CVD), AS WELL AS A METHOD OF MANUFACTURING AN ELECTROLUMINESCENT (EL) DEVICE | Koninklijke Philips Electronics N.V. (NL) | 1996-06-05 | — | — | EP | claimed |
| WO-1995031831-A1 | METHOD OF PROVIDING A FILM OF CONJUGATED, SUBSTITUTED OR UNSUBSTITUTED POLY(P-PHENYLENE VINYLENE) ON A SUBSTRATE BY CHEMICAL VAPOUR DEPOSITION (CVD), AS WELL AS A METHOD OF MANUFACTURING AN ELECTROLUMINESCENT (EL) DEVICE | PHILIPS ELECTRONICS N.V. (NL) | 1995-11-23 | — | — | WO | claimed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-106986742-B | Synthesis method of tetrachloro-p-xylene cyclic dimer | 常州市骏佳化工有限公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-0318836-A2 | Poly(arylene sulfide) process compositions and articles of manufacture | PHILLIPS PETROLEUM COMPANY (US) | 1989-06-07 | — | — | EP | disclosed |
| US-RE30420-E | DIURETIC, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| US-4185992-A | Imidazole derivatives | MAY & BAKER LIMITED (GB) | 1980-01-29 | — | — | US | disclosed |
| US-4112227-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4056533-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS, DIURETICS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
| US-4000294-A | DIURESIS OR SALURESIS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | disclosed |
| US-3992404-A | DIURETICS, SALURETICS, ANTIHYPERTENSIVE AGENTS, AND ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3974144-A | BENZOFURAN, BENZOTHIOPHENE, NAPHTHOFURAN, OPTICAL BRIGHTENER | STERLING DRUG INC. (US) | 1976-08-10 | — | — | US | disclosed |
| US-3952008-A | DIURETIC, SALURETIC, HYPOTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | CYP3A4 3609/4885ALDH1A1 399/4885NPSR1 2379/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | CYP3A4 3609/4885ALDH1A1 399/4885NPSR1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.